Familial mediterranean fever: A critical digest of the 2012-2013 literature

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Eisenstein, Eli M ^a   Berkun, Yackov ^a   Ben Chetrit, Eldad ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Colchicine; Familial mediterranean fever; Interleukin 1; Spondyloarthropathy

Indexed keywords

COLCHICINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

BEHCET DISEASE; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERANCE; EVIDENCE BASED PRACTICE; FAMILIAL MEDITERRANEAN FEVER; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LEG PAIN; MEFV GENE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYRIN GENE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SPONDYLOARTHROPATHY;

ANIMALS; COMORBIDITY; FAMILIAL MEDITERRANEAN FEVER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84884916287     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. BEN-CHETRIT E, LEVY M: Familial Mediterranean fever. Lancet 1998; 351: 659-64.
2. LIVNEH A, LANGEVITZ P, ZEMER D et al.: Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85.
3. BERKUN Y, EISENSTEIN E, BEN-CHETRIT E: FMF - clinical features, new treatments and the role of genetic modifiers: a critical digest of the 2010-2012 literature. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S90-5.
4. FRENCH FMF Consortium: A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25-31.
5. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90: 797-807.
6. CHAE JJ, WOOD G, MASTERS SL et al.: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006; 103: 9982-7.
7. PAPIN S, CUENIN S, AGOSTINI L et al.: The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 2007; 14: 1457-66.
8. YU JW, WU J, ZHANG Z et al.: Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 2006; 13: 236-49
9. GAVRILIN MA, ABDELAZIZ DH, MOSTAFA M et al.: Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol 2012;188: 3469-77.
10. CHAE JJ, CHO YH, LEE GS et al.: Gain-offunction Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011; 34: 755-68.
11. YU JW, FARIAS A, HWANG I, FERNANDESALNEMRI T, ALNEMRI ES: Ribotoxic stress through p38 mitogen-activated protein kinase activates in vitro the human pyrin inflammasome. J Biol Chem 2013; 288: 11378-83.
12. STOFFELS M, SZPERL A, SIMON A et al.: MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis 2013 Mar 16 [Epub ahead of print].
13. ALDEA A, CAMPISTOL JM, AROSTEGUI JI et al.: A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder?. Am J Med Genet A 2004; 124A: 67-73.
14. BOOTH DR, GILLMORE JD, LACHMANN HJ et al.: The genetic basis of autosomal dominant familial Mediterranean fever. QJM 2000; 93: 217-21.
15. CAGLAR MK, ALTUGAN FS, OZYURT H, ATASOY HI: Screening of family members of children with Familial Mediterranean Fever: true-autosomal and pseudo-autosomal inheritance. Acta Reumatol Port 2008; 33: 415-20.
16. BEN-CHETRIT E, PELEG H, AAMAR S, HEYMAN SN: The spectrum of MEFV clinical presentations--is it familial Mediterranean fever only?. Rheumatology (Oxford) 2009; 48: 1455-9.
17. EISENSTEIN EM, WILLIAMS CB: The T(reg)/ Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res 2009; 65: 26R-31R.
18. OVADIA A, LIVNEH A, FELD O et al.: T helper 17 polarization in familial Mediterranean fever. Genes Immun 2013; 14: 212-6.
19. KORN T, BETTELLI E, OUKKA M, KUCHROO VK: IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
20. BEN-CHETRIT E, TOUITOU I: Familial mediterranean Fever in the world. Arthritis Rheum 2009; 61: 1447-53.
21. OZEN S, DEMIRKAYA E, AMARYAN G et al.; for the Paediatric Rheumatology International Trials Organisation (PRINTO ) and the Eurofever Project: Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis 2013 Mar 5. [Epub ahead of print].
22. LANGEVITZ P, LIVNEH A, ZEMER D, SHEMER J, PRAS M: Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 1997; 27: 67-72.
23. KASIFOGLU T, CALISIR C, CANSU DU, KORKMAZ C: The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009; 28: 41-6.
24. BALABAN B, YASAR E, OZGUL A, DINCER K, KALYON TA: Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis. Rheumatol Int 2005; 25: 641-4.
25. BORMAN P, GÖKOGLU F, TASBAS O, YILMAZ M, YORGANCIOGLU ZR: Familial Mediterranean fever-related spondyloarthropathy. Singapore Med J 2009; 50: e116-9.
26. AKAR S, SOYSAL O, BALCI A et al.: High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection. Arthritis Res Ther 2013; 15: R21.
27. LANGEVITZ P, ZEMER D, LIVNEH A, SHEMER J, PRAS M: Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol 1994; 21: 1708-9.
28. KAPLAN E, MUKAMEL M, BARASH J et al.: Protracted febrile myalgia in children and young adults with familial Mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S114-7.
29. ESHED I, KUSHNIR T, LIVNEH A et al.: Exertional leg pain as a manifestation of occult spondyloarthropathy in familial Mediterranean fever: an MRI evaluation. Scand J Rheumatol 2012; 41: 482-6.
30. OZKAN F, CETIN GY, INCI MF et al.: Increased enthesopathy in patients with familial Mediterranean fever: evaluation with a new sonographic enthesitis index. J Ultrasound Med 2013; 32: 325-32.
31. YILMAZ O, KISACIK B, OZKAN F et al.: Does enthesopathy relate to M694V gene mutation in patients with Familial Mediterranean fever?. Clin Rheumatol 2013 Jun 29 [Epub ahead of print].
32. TUFAN A, MERCAN R, TEZCAN ME et al.: Enthesopathy in patients with familial Mediterranean fever: increased prevalence in M694 V variant. Rheumatol Int 2013; 33: 1933-7.
33. KUSHNIR T, ESHED I, HELED Y et al.: Exertional muscle pain in familial Mediterranean fever patients evaluated by MRI and 31P magnetic resonance spectroscopy. Clin Radiol 2013; 68: 371-5.
34. BEN-CHETRIT E, YAZICI H: Thoughts on the proposed links between Behçet's disease and familial Mediterranean fever. Clin Exp Rheumatol 2002; 20 (Suppl. 26): S1-2.
35. TOUITOU I, MAGNE X, MOLINARI N et al.: MEFV mutations in Behçet's disease. Hum Mutat 2000; 16: 271-2.
36. RABINOVICH E, SHINAR Y, LEIBA M, EHRENFELD M, LANGEVITZ P, LIVNEH A: Common FMF alleles may predispose to development of Behçet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007; 36: 48-52.
37. BARUCH Y, DAGAN E, ROSNER I, FIORILLI M, GERSHONI-BARUCH R, ROZENBAUM M: MEFV, TNFRSF1A and CARD15 mutation analysis in Behçet's disease. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S24-S27.
38. YAZICI A, CEFLE A, SAVLI H: The frequency of MEFV gene mutations in Behçet's disease and their relation with clinical findings. Rheumatol Int 2012; 32: 3025-30.
39. ESMAEILI M, BONYADI M, KHABBAZI A et al.: Common MEFV mutations in Iranian Azeri Turkish patients with Behçet's disease. Scand J Rheumatol 2011; 40: 383-6.
40. KIRINO Y, ZHOU Q, ISHIGATSUBO Y et al.: Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the tolllike receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci USA 2013; 110: 8134-9.
41. TWIG G, LIVNEH A, VIVANTE A et al.: Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 2013 Mar. 16 [Epub ahead of print].
42. ZEMER D, LIVNEH A, DANON YL, PRAS M, SOHAR E: Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991; 34: 973-7.
43. BEN-CHETRIT E, AAMAR S: About colchicine compliance, resistance and virulence. Clin Exp Rheumatol 2009; 27 (Suppl. 53): S1-3.
44. ZEMER D, PRAS M, SOHAR E, MODAN M, CABILI S, GAFNI J: Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001-5.
45. TUFAN A, BABAOGLU MO, AKDOGAN A et al.: Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007; 34: 1540-4.
46. OZTURK MA, KANBAY M, KASAPOGLU B et al.: Therepeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S77-S86.
47. BEN-CHETRIT E, TOUITOU I: The impact of MEFV gene identification on FMF: an appraisal after 15 years. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S3-S6.
48. LIDAR M, YONATH H, SHECHTER N et al.: Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012; 12: 72-6.
49. SOYLEMEZOGLU O, ARGA M, FIDAN K et al.: Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 2010; 37: 182-9.
50. MAJEED HA, El-SHANTI H, Al-KHATEEB MS, RABAIHA ZA: Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. Semin Arthritis Rheum 2002; 31: 371-6.
51. GERSHONI-BARUCH R, BRIK R, ZACKS N, SHINAWI M, LIDAR M, LIVNEH A: The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003; 48: 1149-55.
52. SORIANO A, VERECCHIA E, AFELTRA A, LANDOLFI R, MANNA R: IL-1β Biological Treatment of Familial Mediterranean Fever. Clin Rev Allergy Immunol 2013; 45: 117-30.
53. KORCMAZ C: Therapeutic approach to familial Mediterranean fever-related amyloidosis resistant to colchicine. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S104-7.
54. HASHKES PJ, SPALDING SJ, GIANNINI EH et al.: Rilonacept for colchicine-resistant or intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157: 533-41.
55. HENTGEN V, GRATEAU G, KONE-PAUT I et al.: Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum 2013 Jun 3 [Epub ahead of print].
56. BLUM A, GAFNI J, SOHAR E, SHIBOLET S, HELLER H: Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF). Further evidence of its genetic nature. Ann Intern Med 1962; 57: 795-9.
57. DUZOVA A, BAKKALOGLU A, BESBAS N et al.: Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003; 21: 509-14.
58. KOGAN A, SHINAR Y, LIDAR M et al.: Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the car